CLI kills more people than many common cancers and is associated with severe outcomes if left untreated or if the presentation is too late. Yet no program exists to raise public awareness about CLI. The time has come for a call to action for better public CLI awareness, training of CLI specialists, and more data on CLI therapy outcomes.

We are proud to announce the development of the first vascular specialist advocacy group, the CLI Global Society. Join this grassroots movement and contribute to increased awareness, education, training, and development of global standards for clinical evaluation and therapy for the CLI patient. Because a multidisciplinary approach to this complex disease is critical, the Society encourages involvement of vascular specialists, primary care physicians, endocrinologists, podiatrists, and wound care specialists.

The first goal of the Society is to build public and physician awareness of CLI and its treatment options. The Society additionally will work to develop globalized standardization for clinical evaluation, noninvasive and invasive diagnostics, medical therapy, and revascularization for the CLI patient. The Society will work closely with global regulatory agencies to create an understanding of the complexity of treating a patient with CLI and recommend appropriate endpoints for CLI clinical trials.

An enthusiastic group met at the first CLI Global Society membership meeting, held in conjunction with the Amputation Prevention Symposium in Chicago on August 10, 2016. Join the CLI Global Society at www.cliglobalsociety.org and become part of the solution!

Diabetes is undoubtedly the “modern plague.” Despite improvements in access to health care, we are still reeling from the daily struggle against critical limb ischemia (CLI). Patients are surviving longer, have had prior interventions, and are presenting with more complex angiograms and wounds. The CLI “animal” has now become the “beast.” Following are 3 case examples from a dedicated limb-salvage center in Changi General Hospital, Singapore.

In our hospital, limb salvage is undertaken by the vascular surgeons who deal with two of the most pressing issues in diabetic CLI: revascularization as well as soft tissue debridement and reconstruction. We strive to attend to every diabetic CLI case referred to our service within 24 hrs. There is a hybrid operating room available 24/7. Patients undergo simultaneous endovascular and open revascularization as well as infection control, debridements, and minor amputations under regional blocks and sedation (usually an ultrasound-guided popliteal and saphenous nerve block). This is supported by a multidisciplinary team consisting of podiatrist, wound care nurses, endocrinologist and foot and ankle orthopedic surgeons.

**Case Examples**

**Case 1**

A 70-year-old male prior smoker with a past history of a coronary bypass surgery, diabetes, hypertension, and hyperlipidemia presented with gangrene of the left foot for 2 months, refusing intervention, and arrived in our center for a second opinion (Figure 1).
The CSI Orbital Atherectomy System is a percutaneous orbital atherectomy system indicated for use as therapy in patients with occlusive atherosclerotic disease in peripheral arteries and stenotic material from artificial arteriovenous dialysis fistulae. Contraindications for the system include use in coronary arteries, bypass grafts, stents, or where thrombus or dissections are present. Although the incidence of adverse events is rare, potential events that can occur with atherectomy include: pain, hypotension, CVA/TIA, death, dissection, perforation, distal embolization, thrombus formation, hematuria, abrupt or acute vessel closure, or arterial spasm.

Caution:
Federal law (USA) restricts this device to sale by, or on the order of, a physician.


When you see calcium, think DIAMONDBACK.

The CSI Orbital Atherectomy System is a percutaneous orbital atherectomy system indicated for use as therapy in patients with occlusive atherosclerotic disease in peripheral arteries and stenotic material from artificial arteriovenous dialysis fistulae. Contraindications for the system include use in coronary arteries, bypass grafts, stents, or where thrombus or dissections are present. Although the incidence of adverse events is rare, potential events that can occur with atherectomy include: pain, hypotension, CVA/TIA, death, dissection, perforation, distal embolization, thrombus formation, hematuria, abrupt or acute vessel closure, or arterial spasm.

Caution: Federal law (USA) restricts this device to sale by, or on the order of, a physician.


When you see calcium, think DIAMONDBACK.

To see our clinical studies, visit WhyOrbital.com
The introduction of new technologies and techniques has led to a significant increase in the success rate of endovascular procedures, which in turn has led to an increasing acceptance of endovascular therapy as a first-line approach. Dedicated chronic total occlusion (CTO) guidewires, crossing devices, re-entry systems, and new stent platforms with significantly improved crush-resistant forces are felt to have helped to push the field forward, beyond previously existing limitations. Consequently, the complexity of cases that are being offered percutaneously transluminal angioplasty (PTA) is further increasing. Highly complex lesions run the gamut from redo procedures, reclosures after endovascular or failed surgical treatments, extreme calcification (long and circumferential), total and long occlusions of 2 and 3 tibial vessels, occluded inframalleolar arteries with need for pedal loop reconstruction, and even endovascular treatment of heavily calcified lesions in the common femoral artery, a territory that has been the last resort to be approached via endovascular means. To deal with such cases, endovascular techniques must be constantly modified and improved. Herein, the authors aim to describe some techniques and technologies that we have found to be very helpful in dealing with extremely complex CTOs.

Flush-occlusions of the superficial femoral artery (SFA) harbor significant challenges for an endovascular treatment (Figure 1A). Especially if surgical treatment, such as bypass or thromboendarterectomy, have preceded, an antegrade guidewire access to the CTO can be impossible, due to extensive scarring. In cases of failure, a retrograde approach may be the only solution. But even then, especially after previous surgery of the femoral bifurcation, the guidewire tends to travel subintimally into the common femoral artery (CFA) and consecutive treatment steps may jeopardize the profund femoris. For a precise re-entry of the guidewire from retrograde back into the common femoral artery (CFA), the use of a re-entry device is very helpful. They are either inserted via the popliteal artery or, as we have described previously,1 through a retrograde approach via the distal femoral artery. However, the insertion of a re-entry device requires a 6 Fr sheath, which increases the risk for bleeding at the distal access site where closure devices might be impossible or hazardous to use.

In such situations, we seek to reduce the risk of bleeding as much as possible by trying to gain access directly into the occluded SFA (Figures 1B–1D). In cases of a typically long SFA CTO, this technique is advantageous because the access site can be chosen over the whole length of the artery (for example, into a more proximal and therefore rather

Continued on page 12
How I Fit CLI Procedures Into My Busy Schedule

Tino Pena, MD
From Baptist Hospital of Miami, Miami, Florida.

How can we “fit in” a critical limb ischemia (CLI) procedure to a day that is already a full day in the procedure suite as well as a full schedule of patients to see the office? Can we plan for these cases? How can we include them in our already busy schedules? The ability to be an effective operator and properly treat patients with CLI requires multiple moving parts. The clock begins with a phone call or consult from the patient, referring physician, or CLI team member. The first step to a successful interaction involves the ability to quickly evaluate a patient who has been referred. Patients with CLI require prompt treatment. The initial evaluation usually provides the necessary information to properly triage the patient and establish a “pretty good” idea when the patient will need to be treated. Even though the revascularization plan is far from complete, the urgency of the procedure can usually be established after the initial evaluation.

The steps required before the patient is brought to the endovascular suite can be numerous. Understanding the complexity of treatment before the procedure is undertaken requires excellent pre-procedural evaluation. The patient is evaluated for multiple important issues including renal insufficiency, iodine allergy, and the presence of anticoagulants. Aside from a thorough history and physical examination, pre-procedural imaging is usually acquired with a complete noninvasive arterial examination that will likely include digital phlebography. Many patients will then receive an MRA or a CTA depending on the urgency of the therapy and the patient’s possible contraindications (bilateral dialysis, renal insufficiency, pacemaker, iodine allergy).

The challenges with preparing these patients with CLI for a procedure can be numerous. The patients will require proper medical optimization. This will require the assessment and management of antiplatelet medications, diabetic medications, and blood pressure management. A conversation with the wound care team is important to determine the overall treatment goals to coordinate the patient’s care, including potential debridement. The planning of the eventual revascularization procedure and treatment plan for these patients will rely on the physical examination, pre-procedural imaging, and discussions with the CLI team. Many CLI teams have found great success using allied health personnel who becomes the central spoke in the communication hub.

One of the greatest challenges of being able to schedule and perform CLI procedures is that many of these procedures need to be performed urgently. There is concern in many of these patients that a long delay may lead to further tissue threat. Additionally, patients may suffer from rest pain, further exacerbating the treatment urgency. Usually they are scheduled and performed within 1 or 2 days of being evaluated in the office. In the outpatient setting, the ability to treat a patient quickly may be limited by the patient’s comorbidities. As such, proper preoperative planning and treatment plan for these patients will rely on the physical examination, pre-procedural imaging, and discussions with the CLI team.

The treatment plan for these patients usually provides the necessary information to properly triage the patient and establish a “pretty good” idea when the patient will need to be treated. Even though the revascularization plan is far from complete, the urgency of the procedure can usually be established after the initial evaluation.

The steps required before the patient is brought to the endovascular suite can be numerous. Understanding the complexity of treatment before the procedure is undertaken requires excellent pre-procedural evaluation. The patient is evaluated for multiple important issues including renal insufficiency, iodine allergy, and the presence of anticoagulants. Aside from a thorough history and physical examination, pre-procedural imaging is usually acquired with a complete noninvasive arterial examination that will likely include digital phlebography. Many patients will then receive an MRA or a CTA depending on the urgency of the therapy and the patient’s possible contraindications (bilateral dialysis, renal insufficiency, pacemaker, iodine allergy).

The challenges with preparing these patients with CLI for a procedure can be numerous. The patients will require proper medical optimization. This will require the assessment and management of antiplatelet medications, diabetic medications, and blood pressure management. A conversation with the wound care team is important to determine the overall treatment goals to coordinate the patient’s care, including potential debridement. The planning of the eventual revascularization procedure and treatment plan for these patients will rely on the physical examination, pre-procedural imaging, and discussions with the CLI team. Many CLI teams have found great success using allied health personnel who becomes the central spoke in the communication hub.

One of the greatest challenges of being able to schedule and perform CLI procedures is that many of these procedures need to be performed urgently. There is concern in many of these patients that a long delay may lead to further tissue threat. Additionally, patients may suffer from rest pain, further exacerbating the treatment urgency. Usually they are scheduled and performed within 1 or 2 days of being evaluated in the office. In the outpatient setting, the ability to treat a patient quickly may be limited by the patient’s comorbidities. As such, proper preoperative planning and treatment plan for these patients will rely on the physical examination, pre-procedural imaging, and discussions with the CLI team.

The treatment plan for these patients usually provides the necessary information to properly triage the patient and establish a “pretty good” idea when the patient will need to be treated. Even though the revascularization plan is far from complete, the urgency of the procedure can usually be established after the initial evaluation.

The steps required before the patient is brought to the endovascular suite can be numerous. Understanding the complexity of treatment before the procedure is undertaken requires excellent pre-procedural evaluation. The patient is evaluated for multiple important issues including renal insufficiency, iodine allergy, and the presence of anticoagulants. Aside from a thorough history and physical examination, pre-procedural imaging is usually acquired with a complete noninvasive arterial examination that will likely include digital phlebography. Many patients will then receive an MRA or a CTA depending on the urgency of the therapy and the patient’s possible contraindications (bilateral dialysis, renal insufficiency, pacemaker, iodine allergy).

The challenges with preparing these patients with CLI for a procedure can be numerous. The patients will require proper medical optimization. This will require the assessment and management of antiplatelet medications, diabetic medications, and blood pressure management. A conversation with the wound care team is important to determine the overall treatment goals to coordinate the patient’s care, including potential debridement. The planning of the eventual revascularization procedure and treatment plan for these patients will rely on the physical examination, pre-procedural imaging, and discussions with the CLI team. Many CLI teams have found great success using allied health personnel who becomes the central spoke in the communication hub.

One of the greatest challenges of being able to schedule and perform CLI procedures is that many of these procedures need to be performed urgently. There is concern in many of these patients that a long delay may lead to further tissue threat. Additionally, patients may suffer from rest pain, further exacerbating the treatment urgency. Usually they are scheduled and performed within 1 or 2 days of being evaluated in the office. In the outpatient setting, the ability to treat a patient quickly may be limited by the patient’s comorbidities. As such, proper preoperative planning and treatment plan for these patients will rely on the physical examination, pre-procedural imaging, and discussions with the CLI team. Many CLI teams have found great success using allied health personnel who becomes the central spoke in the communication hub.

One of the greatest challenges of being able to schedule and perform CLI procedures is that many of these procedures need to be performed urgently. There is concern in many of these patients that a long delay may lead to further tissue threat. Additionally, patients may suffer from rest pain, further exacerbating the treatment urgency. Usually they are scheduled and performed within 1 or 2 days of being evaluated in the office. In the outpatient setting, the ability to treat a patient quickly may be limited by the patient’s comorbidities. As such, proper preoperative planning and treatment plan for these patients will rely on the physical examination, pre-procedural imaging, and discussions with the CLI team. Many CLI teams have found great success using allied health personnel who becomes the central spoke in the communication hub.

One of the greatest challenges of being able to schedule and perform CLI procedures is that many of these procedures need to be performed urgently. There is concern in many of these patients that a long delay may lead to further tissue threat. Additionally, patients may suffer from rest pain, further exacerbating the treatment urgency. Usually they are scheduled and performed within 1 or 2 days of being evaluated in the office. In the outpatient setting, the ability to treat a patient quickly may be limited by the patient’s comorbidities. As such, proper preoperative planning and treatment plan for these patients will rely on the physical examination, pre-procedural imaging, and discussions with the CLI team. Many CLI teams have found great success using allied health personnel who becomes the central spoke in the communication hub.

One of the greatest challenges of being able to schedule and perform CLI procedures is that many of these procedures need to be performed urgently. There is concern in many of these patients that a long delay may lead to further tissue threat. Additionally, patients may suffer from rest pain, further exacerbating the treatment urgency. Usually they are scheduled and performed within 1 or 2 days of being evaluated in the office. In the outpatient setting, the ability to treat a patient quickly may be limited by the patient’s comorbidities. As such, proper preoperative planning and treatment plan for these patients will rely on the physical examination, pre-procedural imaging, and discussions with the CLI team. Many CLI teams have found great success using allied health personnel who becomes the central spoke in the communication hub.
ACHIEVE MORE TOGETHER

The perfect combination for crossing complex lesions

Glidewire Advantage®
Peripheral Guidewires

Navicross®
Support Catheters

Pinnacle Destination®
Guiding Sheath

Committed to helping you do more
Learn about our hands-on training and expert clinical support.

Phone: 800.862.4143  terumois.com/together

For Rx only. Before using refer to Instructions for Use for indications, contraindications as well as warnings and precautions @ terumois.com
Save Her Leg: My Patient Is Not Too Old or Too Sick!

Successful Peripheral Vascular Intervention in a Patient With Rutherford Category IV Critical Limb Ischemia

Guy Pupp, DPM, FACFAS; Patrick Alexander, MD, FACC, FSCAI; Mahomad Al Sawah, DPM; Meaghan Stoinski, DPM

From Providence Hospital Amputation Prevention Center, Southfield, Michigan, and Providence Hospital, Southfield, Michigan.

A dedicated team approach using contemporary technology leads to successful limb salvage, even with significant pathology.

Figure 1. Initial presentation.

Guy Pupp, DPM, FACFAS

Salvaging an ischemic limb necessitates wide resection of all affected, nonfunctional tissue. Rutherford Category VI classification for vascular disease manifestations is graded clinically as major tissue loss behind transmetatarsal level with unrecoverable foot functionality. Time is tissue loss for patients with critical limb ischemia (CLI); without perfusion, our tissue dies and becomes a magnet for infection. In addition, morbidity and mortality rates are astonishingly high after major lower extremity amputations, which often become the treatment for patients with CLI. We report successful limb salvage in a patient with CLI after undergoing extensive peripheral vascular intervention followed by podiatric surgical revision. In a multidisciplinary setting with skilled providers, limb salvage is possible, even in the most challenging cases.

Case Report

An 89-year-old black female was referred to the first author for a second opinion on her ischemic left transmetatarsal amputation site. Past medical history for the patient included peripheral vascular disease (PVD) with claudication status post multiple peripheral vascular interventions, anemia, atrial fibrillation, and 40 pack-year history of tobacco use with 10 years since cessation. Risk factors for PVD included age and tobacco use.

The pathological course began 3 years ago, when a nonhealing wound on the patient’s left third toe resulted in toe amputation following her first left lower extremity peripheral vascular intervention at an external facility. Despite the initial peripheral intervention, gangrene progressed to all remaining toes of the left foot. She then underwent a series of endovascular interventions at an external facility. The patient’s final angiogram at the external facility 6 months ago revealed 100% left superficial femoral artery (SFA) in-stent restenosis, as well as posterior tibial artery, peroneal artery, and tibiopedal (TP) trunk occlusions. Peripheral intervention was performed including balloon angioplasty x3 of the left SFA, peroneal and TP trunk followed by subsequent left transmetatarsal amputation 1 week later. The procedures failed, and the patient’s lower extremity was deemed nonsalvageable. Her physicians recommended a below-knee amputation.

Upon refusal of the amputation, the patient was treated with local wound care and hyperbaric oxygen therapy for 3 months. The patient sought out opinions from providers at external facilities, all of whom recommended the below-knee amputation. Her limb ischemia progressed and she became completely bedbound due to unbearable pain. She was referred to our limb salvage team at Providence Hospital. At initial evaluation, the patient was found to have anemia, leukocytosis, and acute infectious components including osteomyelitis to her ischemic amputation site. She was evaluated and referred to our interventional cardiologist who performed an angiogram with extensive peripheral vascular intervention (PVI) to the left lower extremity (Figure 1). Interventions included drug-eluting stents to the popliteal, tibio-peroneal trunk (TPT) and peroneal arteries, resulting in 0% stenosis from 100% at the beginning of the procedure; 3 lesions in the vascular tree underwent angioplasty as well. The intervention was followed 3 days later by a left revisional Chopart amputation, removing all nonviable soft tissue and osteomyelitic bone by the podiatry team. The patient still had a small soft-tissue defect at the amputation site. Two months later, the podiatry team applied an amniotic stem cell membrane biologic dressing to the residual small
soft-tissue defect. Close follow-up was maintained with no weight-bearing activity until the left Chopart amputation site was healed completely, as noted three months post PVI.

**DISCUSSION**

This case describes a geriatric female with a past history of nicotine use who developed gangrene and CLI. She presented to another institution and after multiple unsuccessful vascular interventions and partial foot amputations, she was referred for a below-the-knee amputation. Utilizing aggressive contemporary technology, successful limb salvage can be achieved in most cases.

Understanding the epidemiology of CLI patients with a major amputation, she would be wheelchair bound for the remainder of her life, which would also be shortened. Her inability to ambulate independently would also affect her quality of life. There is also significant mortality and morbidity in patients undergoing a major amputation such as above- or below-knee amputation. The cost of a lower-extremity prosthetic ranges from $5,000 to $30,000 per prosthetic device without replacement or maintenance costs, which are significant.

In the case of this 89-year-old female patient who had undergone multiple revascularizations and failed prior partial foot amputations, successful peripheral vascular intervention followed by a revised partial foot amputation avoided a below-the-knee major amputation.

By utilizing a multidisciplinary skilled team to achieve limb salvage, we can prolong life and functional status of patients suffering from severe peripheral vascular disease and critical limb ischemia. This case demonstrates the fact that a dedicated team approach using contemporary technology leads to successful limb salvage, even with significant pathology. We feel major amputations can many times be avoided, and that there are no patients too old or too sick.

**REFERENCES**


Examination reveals signs of congestive heart failure with lower-limb edema and orthopnea. In the work-up, a cardiac echocardiography revealed an ejection fraction of 50% and normal renal function. Preprocedure duplex ultrasound reveals multivessel, multilevel disease typical of diabetics who smoke. There was a superficial femoral artery (SFA) and popliteal artery chronic total occlusion (CTO) and a posterior tibial artery (PTA) stenosis. He was optimized with diuresis for 72 hours and underwent a left lower limb angioplasty via the right femoral approach and a simultaneous transmetatarsal amputation. This was done under intravenous sedation and a popliteal nerve regional block (Figure 2).

The vessels were heavily calcified and re-entry with a stiff 0.035˝ Terumo wire failed. A retrograde puncture of the posterior tibial artery was performed under ultrasound guidance. After snaring the retrograde 0.018˝ wire with an angled catheter and reversal of the wire, predilatation and lesion preparation was done with a high-pressure 6 mm Conquest Balloon (Bard Peripheral Vascular). In view of the severe recoil seen and the need to optimize the inflow, the SFA and popliteal artery were stented with a 5 mm Supera stent (Abbott Vascular) with good results. Supplementary balloon angioplasty of the posterior tibial artery was done with a 3 mm Armada 14 PTA Catheter (Abbott Vascular). A transmetatarsal amputation of the toes was performed simultaneously. Post procedure, the patient required 1 week stay for optimization of fluid status and wound care and was started on life-long dual antiplatelet therapy (DAPT) in view of the advanced nature of arterial disease and stents. Negative pressure wound therapy was started (VAC therapy). The patient achieved complete wound healing in 9 months. He was given insoles with a toe filler and he remains wound free and free of cardiovascular events (Figure 3). On 3-year follow-up, he is ambulating without a walking aid.

Case 2

The second patient presented with a history of diabetes, hypertension, and hyperlipidemia and extensive gangrene over the left heel. On examination she had lower-limb edema and absent pulses over the foot. Dry gangrene of the left heel almost extended to, but did not involve, the calcaneal bone (Figure 4).

Preprocedure work-up showed a preserved cardiac ejection fraction, borderline renal function, and severe proteinuria. She was diagnosed with critical limb ischemia and nephrotic syndrome, and was treated with diuresis, DAPT, and angiotensin receptor blockade (ARBs). She underwent a left-leg angioplasty and simultaneous debridement of the gangrene in our hybrid operating room under sedation and a popliteal nerve block. Preintervention angiogram revealed multivessel, multilevel disease and calcification typical of diabetic angiopathy. Based on the angiosome concept and the severity of the soft tissue loss, an all-out attempt was made to revascularize as many vessels as possible. Good vessel patency was also required in anticipation of prolonged wound healing. Severe recoil of the popliteal artery and dissections of the proximal tibial vessels were seen after angioplasty (Figure 5).

We decided to recruit her into a study (Drug Impregnated Bioabsorbable Stent in Asian Population Extremity Arterial Revascularization – DISAPEAR study) and proceeded with a combination of an Absorb bioabsorbable vascular scaffold (Abbott Vascular) and Supera Stent (Abbott Vascular) to reconstruct the bifurcation despite moderate calcification.

Postprocedure wound care was prolonged and the patient achieved wound healing 6 months later. Serial clinical examinations and duplex ultrasounds at 6, 12, 18, and 24 months revealed good flow.
New Guide Wires

ASAHI Gladius® 0.014/0.018 Workhorse

ASAHI Halberd® 0.014/0.018 Complex Lesion

ASAHI Gaia® PV 0.018 Complex Lesion

New Micro Catheter

ASAHI Corsair® Armet®

Durable metal tip

Super SHINKA-Shaft
Low profile, supportive catheter body, excellent torque
Surgical and endovascular options must be considered for revascularization.

KUM from page 8

with intact distal pulses as well as no evidence of restenosis within the Supera and bioabsorbable vascular scaffold. She remains wound free at 24 months (Figure 6).

Case 3

The last patient is also a 75-year-old female with a 20-year history of diabetes. She had previous interventions and 3 toes amputated several years ago. She returned with gangrene of her remaining first and second toes. An attempt at intervention failed due to a lack of discernible runoff, calcified SFA, and recurrent in-stent restenosis of the popliteal artery despite prior drug-coated balloon angioplasty.

In view of the “desert foot” and severe in-flow lesions, a surgical bypass to the deep veins of the foot (deep vein arterIALIZATION) was performed with a hybrid approach. A 5-mm reinforced polytetrafluoroethylene graft was tunneled to above the ankle. The distal anastomosis was created percutaneously with a 5-mm Viabahn endoprosthesis (W.L. Gore) into the posterior tibial vein, for a suture-less anastomosis. Postprocedure perfusion angiogram showed brisk flow (Figure 7).

The wound was left to demarcate and was subsequently debrided. VAC therapy was started and full wound closure was possible with a split skin graft. Improvements in transcutaneous oxygen levels (TCPO2) were also seen (Figure 8).

The first case illustrates the importance of inflow treatment in a diabetic with multilevel disease. Balloon angioplasty is often handicapped by recoil, which may not be evident on 2-view angiography. In a calcified CTO, mechanical scaffolding with a dedicated stent with high radial force is essential to give a “few-pop bypass” equivalent for wound healing. Early results from the SUPERSUB study of the Supera stent suggest good clinical and patency outcomes for long SFA CTOs as compared to standard nitinol stents.1

Aggressive wound care and early return to ambulation are our ultimate goals to ensure a good angiographic result is paired with a good clinical result. Risk factor modification with statins and DAPT are essential in this high-risk group.

The second case illustrates the challenges in diabetic CLI. To date, plain old balloon angioplasty (POBA) seems to be the standard of care in moderate-length to long-length lesions. Recoil after POBA is more common than many clinicians think.2 In a small study, recoil of >10% was observed in 97% of a cohort of 30 consecutive patients with a mean luminal diameter (MLD) compromise of 29% according to an angiogram taken 15 minutes after initial postangioplasty angiogram. Small- vessel diameters in addition to recoil may not only compromise the absolute blood volume for wound healing, it may also, in theory, compromise patency. Bioabsorbable stents have proven results in the coronary space and offer the promise of an antirestenotic, nonpermanent scaffold. We utilize a combination of several bioabsorbable vascular scaffolds to achieve reconstruction of the trifurcation with good patency and clinical results at 2 years for a patient with Rutherford VI heal gangrene.

The third case is an example of a patient with “no-option” CLI. A combination of inflow in-stent restenosis and the lack of any discernible run-off for conventional distal bypass or distal balloon angioplasty is a challenge. Recent publications on venous arterIALIZATION seems to hold promise.3 Conventional deep-vein bypass is technically challenging due to the small calibre of the deep veins and propensity for twisting to occur. We utilize a hybrid technique with a “suture-less distal anastomosis” with a Viabahn covered stent. In combination with aggressive wound care and skin coverage, we managed to achieve full wound healing at 8 months. A completely percutaneous approach with the Linflow device is under investigation.

In summary, CLI remains a challenging disease to treat. Surgical and endovascular options must be considered for revascularization. Clinicians continue to push the envelope to find solutions to treat a disease that knows no limits. Aggressive wound care to heal wounds and return to walking should be emphasized as endpoints for CLI.

REFERENCES


Recurring in-stent restenosis is a problem.

Turbo-Power™ Laser Atherectomy Catheter is the solution.
Dedicated chronic total occlusion guidewires, cross-angulation, and new stent platforms with significantly improved crush-resistant forces are felt to have helped to push the field forward, beyond previously existing limitations.

The complexity of the flush-occlusion determines the devices to be used to successfully perform guidewire passage via the access site. In the case in which a re-entry device is felt to be necessary, a 6 Fr sheath is directly inserted into the occluded SFA from a retrograde approach. Another alternative could be the use of a newer crossing device, the Wingman Crossing Catheter (Reflow Medical), which is compatible with different guidewire sizes (0.014”, 0.018”, and 0.035”) as seen in Figure 1E. The Wingman Crossing Catheter is an over-the-wire braided catheter with an extendable radiopaque needle-like tip that is manually controlled by a handle to engage with the lesion. A push-and-twist motion allows penetration of the tip and further advancement of the wire.

However, despite this armamentarium, with severe scarring or even transection of the SFA during surgery, or if the proximal SFA has been utilized as a patch for the profundar artery, guidewire passage into the CFA from a retrograde approach might seem impossible. In these cases, we found the use of a metallic needle device like the Brockenbrough needle (Figures 1F-1H) to be a solution. The Brockenbrough needles is used in cardiology to traverse the atrial septum. It comes with a stable metallic tube, which requires a 6 Fr sheath. However, the needle itself offers enough stability if used without it and requires only a 4 Fr sheath. Any 0.018” or 0.014” guidewire can be used through this needle. Its use is not approved for peripheral arteries, but successful passage of a severely calcified SFA lesion using this device has been described in the literature. Once guidewire passage has been accomplished, scarring from surgery might hinder further steps (Figure 1I). Bleeding from the retrograde 6 Fr access through the occluded SFA is easily controlled by balloon angioplasty and stenting, and potentially implantation of a Viabahn endoprosthesis (W.L. Gore), during treatment. In a series of 56 patients at our center, the retrograde puncture of an occluded SFA segment was feasible

Figure 1. Long flush superficial femoral artery (SFA) chronic total occlusion after previous surgery with a prosthetic femoral-popliteal segment, prosthetic bypass and repeat surgery for recollusions and finally removal due to prosthesis-infection. Arrow indicates patent distal P1 segment of the popliteal artery (A). An 18-gauge needle is shown in alignment to calcification (arrows) of the SFA on fluoroscopy (B). Guidewire insertion into the occluded SFA after a 90° tilt of the C-arm (C). After an initially subintimal course, the guidewire forms a larger loop revealing perforation in the proximal part of the SFA (D). Wingman Crossing Catheter (Reflow Medical) (E). The Brockenbrough-needle (F) can be bent as required. Correct position of the needle tip should be checked in different angulations before puncturing (G). A guidewire from above can serve as a target (H). After snaring of the guidewire from above, balloon inflation proved to be challenging. Arrow indicates the site of passage into the common femoral artery (CFA) (I). After completion of guidewire passage at the proximal former bypass, anastomosis passage of the distal bypass anastomosis also proved to be difficult due to removal of the infected bypass. Retrograde insertion of the Brockenbrough needle via the proximal anterior tibial artery (J), Brockenbrough needle (open triangles) passage through the distal anastomosis site (open arrow; guidewire perforation from above; black arrow; retrograde 6Fr sheath for guidewire passage to the CFA still in place). Result after implantation of covered Viabahn covered stents (K, L).
implant the stent. In such situations, we implant a Viabahn endoprosthesis to seal the intended rupture and reinforce it with a Supera stent to overcome the recoil forces of the calcified plaque. This facilitates treatment without significant residual stenosis. Aggressive percutaneous transluminal angioplasty of the artery can be painful, therefore we administer local anesthetic percutaneously to the most severely calcified segments of the artery (for this purpose, a 9 cm 21-gauge needle is helpful), or we perform the procedure under general anesthesia (Figure 2).

The two techniques described here may enable interventionalists to offer an endovascular approach to some of the most severe forms of peripheral arterial occlusive disease if surgery is felt to be problematic for these patients.

Address for correspondence: Andrej Schmidt, MD, Department for Interventional Angiography, University Clinic Leipzig, Philipp-Rosenthal-Strasse 27c, 04103 Leipzig, Germany. Email: Andrej.schmidt@medizin.uni-leipzig.de

Disclosures: Andrej Schmidt, MD, is a consultant for Abbott Vascular, Boston Scientific, C.R. Bard, Cook Medical, Cordis, Intactvascular, Medtronic, ReFlow Medical, Spectranetics, Upstream Peripheral and is a former stockholder of IDEV Technologies. Dierk Scheinert, MD, is a consultant for Abbott Vascular, Boston Scientific, C.R. Bard, Cook Medical, Cordis, Gardia Medical, Medtronic, ReFlow Medical, TriReme Medical, Upstream Peripheral and is a former stockholder of IDEV Technologies.

REFERENCES
Why CLI Patient Awareness Is Important – You Don’t Know What You Don’t Know

Desmond Bell, DPM, CWS
From First Coast Cardiovascular Institute, Jacksonville, Florida.

S
creenings for cancer are part of a comprehensive physical examination, with the benefits of early detection indisputable. The idea that physicians, nurse practitioners, and patients would rather wait for a suspicious lesion to metastasize rather than seek proactive intervention seems outrageous, yet this is the mindset that is still pervasive when it comes to peripheral arterial disease (PAD) as it converts to critical limb ischemia (CLI). By this time, most of us who have dedicated our professional careers to lower-extremity preservation and unnecessary amputation prevention comprehend all that PAD and CLI entail. The 5-year mortality rates when compared to various cancers, the odds of amputation of the contralateral limb, the bleak likelihood of ever amputating with a prosthesis, not to mention the undignified downward spiral this group of patients experiences before departing this life. We know what these patients face and it motivates us to prevent such tragedy on a daily basis.

The emergence of technologies engineered to open occluded coronary as well as peripheral arteries has undoubtedly been responsible for extending and improving the quality of life for countless patients, many of them suffering from severe PAD and CLI. Amputation rates are apparently on the decline, which speaks to the acceptance of the team approach to limb preservation, breakthroughs in devices, and the positive impact team and technology share in this perceived improvement.

Accompanying this outcry would be a call to action with patient education and public awareness as key components to successful intervention in preventing those unaware they have PAD from deteriorating into those with CLI.

The number of educational conferences and publications speaks to the ever-increasing awareness of CLI among specialized healthcare providers and industry. That being stated, most primary care providers “do not have the time” to look for PAD or CLI unless symptoms are conveyed by patients. Routine inspection of the feet to palpate pulses or inspect the quality of skin is just not generally performed in providers’ offices.

Calling on the effectiveness of the “pink ribbon” and all it represents is a single white sock worn either outside a pants leg or solely on an exposed leg. Photos can be taken and posted on social media. White socks are worn in public to extend awareness and education campaign that will impact those afflicted with PAD in the same manner that breast cancer has been impacted by its incredibly successful public relations efforts. Early detection through screenings and education of the public can prevent countless legs from future amputation and prevent individuals and families from avoidable pain and suffering, not to mention reduce the economic impact on our healthcare system.

The Save A Leg, Save A Life Foundation is poised to begin such a campaign. An immediate goal of SALSAL is to raise awareness of the public regarding PAD and CLI through the “White Sock Campaign,” a grassroots social media effort that will occur this and every September. Anyone can participate; all it requires is a single white sock worn either outside a pants leg or solely on an exposed leg. Photos can be taken and posted on social media. White socks worn in public will certainly create stares and questions from those inquisitive enough to ask, “What’s with the white sock?” This creates teaching moments and opportunities to engage the public in dialogue, an evaluation converted to action in the form of an individual asking their doctor to be screened for PAD.

CLI Case Study

A 56-year-old Hispanic female presented in 2015 with a new onset of a “bruised left leg” 3 days earlier. The patient is diabetic and had an extensive tobacco history, but declared smoking cessation 5 days earlier. She had a history of type 2 diabetes, essential hypertension, hypercholesterolemia, congestive heart failure, deep venous thrombosis, and PAD.

Surgical history included coronary artery bypass graft, back and carpal tunnel, and prior amputation of her left great toe nearly 20 years prior.

The vascular technician discovered high-grade stenosis of the left proximal to mid superficial femoral artery (SFA), high-grade stenosis of the proximal left profunda with additional findings of blockage at the anterior tibial artery, dorsalis pedis and the posterior tibial artery. The left leg was cold and the toes ischemic and dry gangrene present, with slough of skin and extensive soft-tissue necrosis. The patient had intractable pain.

The patient received endovascular intervention by an interventional cardiologist. Procedures included atherec-tomy of the left proximal SFA occlusion and placement of 7 mm x 100 mm drug-eluting stent at the mid SFA. Brisk flow was observed post procedure with left foot supplied by the peroneal artery and the distal peroneal artery supplying a patent plantar artery.

Amputation rates are apparently on the decline, which speaks to the acceptance of the team approach to limb preservation, breakthroughs in devices, and the positive impact team and technology share in this perceived improvement.

The patient underwent transmetatarsal amputation by a podiatrist because digits were beyond salvage. The plantar aspect of the foot remained viable while areas of slough along the dorsum of the foot and anterior ankle progressed to eschar in subsequent weeks following procedures.

The patient was managed for wound care by podiatry as an outpatient on a weekly basis, with home nursing providing dressing changes as directed by podiatry. Regular debridement of the wound was performed, including excision of eschar upon demarcation contrasting presence of underlying viable tissue, as well as 3 applications of living skin substitute.

The patient remains on dual antiplate-let therapy and is seen for regular arterial ultrasound every 3 months. Podiatry has continued following the patient weekly to biweekly with regular handheld Doppler evaluation during wound-care visits. The patient is now weight bearing and has begun gait training with anticipa- tion of full weight bearing in diabetic shoes and inserts in the near future.

Conclusion

Critical limb ischemia needs a public awareness and education campaign that will impact those afflicted with PAD in the same manner that breast cancer has been impacted by its incredibly successful public relations efforts. Early detection through screenings and education of the public can prevent countless legs from future amputation and prevent individuals and families from avoidable pain and suffering, not to mention reduce the economic impact on our healthcare system.

References

Your essential 4 Fr tools
below the knee

CXI® Support Catheter
Coaxial system
4 Fr | 2.6 Fr | 2.3 Fr

Compatible 4 Fr products

4 Fr
Flexor® Shuttle® Tibial Guiding Sheath

.014"
Approach® CTO Microwire Guide

.014” compatible
Advance® 14LP Low-Profile PTA Balloon Dilatation Catheter

Download our infrapopliteal procedure guide.
cookmedical.com/cli
Healing Wounds and Preventing Amputations With a Team-Based Approach

A.E. Foster, FNP-BC, H.L. Volkema, FNP-BC, Gwennan Engen, BSN, RN
From Metro Health Hospital, Wyoming, Michigan

Communication, collaboration, and multidisciplinary approach are terms heard in healthcare on a daily basis. All are necessary to provide optimal patient care. A large number of patients requiring the use of endovascular, wound, and infectious disease (ID) specialties are treated at our institution. Due to a steady increase in patients who have peripheral vascular disease and wounds, these specialists recognized the need to enhance communication and collaboration across specialties. These efforts improved patient outcomes, including reducing amputation rates and lowering median days for wound healing. This paper describes components of a highly effective multidisciplinary approach that matured over time at a single institution.

The providers quickly recognized that ancillary staff members are also important components of the multidisciplinary team. Nursing staff members who worked on endovascular cases were trained in wound care and spent time shadowing the wound staff, observing clinic flow, patient care, and different approaches to established goals. Nursing staff from wound care also had the opportunity to shadow endovascular staff to meet the same objectives. Nurse practitioners and physician assistants in both specialties also participated in this shadowing experience, gaining a greater understanding of each discipline’s preferred diagnostic testing and treatment modalities.

Leadership worked to develop changes in the scheduling process and assigned a liaison from each specialty as an initial point of contact for any urgent referrals, testing, or communication. This allows patients to be seen by wound and endovascular providers in a more timely manner, often being seen by each specialist within the same day. Infectious disease became part of this standard too, allowing for closer outpatient follow-up with the already meticulously managed inpatient cases.

To continue development of this interdisciplinary team, quarterly meetings were instituted that are open to all who work in the specialties of wound, endovascular, and ID. Leadership, quality, and research also have representation. The meetings serve as a forum for open communication in a positive setting. The face-to-face interaction allows time for stimulating discussion regarding what is working well and where the challenges exist. Time is provided to brainstorm and share ideas for improvement, and workgroups are assigned for those tasks that cannot be accomplished during the scheduled meeting time. Also, time in the meeting is reserved for a provider from one of the specialties to educate the group on a topic particularly useful or pertinent in their respective area of expertise.

Recent presentation topics include education on endovascular procedures, hyperbaric oxygen therapy guidelines, and new updates on the treatment of how each individual service uniquely contributes to the healing process. This, in turn, led to more efficient working relationships.

Frequent face-to-face interaction evolved and is now a routine aspect of the multidisciplinary team approach. All disciplines practice on the same hospital campus, and cell phone numbers, pager numbers, and inbox messaging systems are shared amongst the team members. It is expected that the lines of communication are always open when needed. Despite different call and clinic schedules, providers save the more personal methods of communication for emergent situations.

The development of a cohesive team approach begins at the provider level (including physicians, nurse practitioners, and physician assistants). Endovascular, wound, and ID specialties had long excelled in each of their respective areas. Over time at our institution, the development of professional relationships brought about awareness of the differences and respect for the strengths within each specialty. Through genuine concern for achieving the absolute best patient outcomes, the focus shifted to learning from each other. These relationships were then deeply rooted in mutual respect, with a greater comprehensive understanding of how each individual service uniquely contributes to the healing process. This recognition led to more efficient working relationships. Frequent face-to-face interaction allowed time for face-to-face interaction allows time for stimulating discussion regarding what is working well and where the challenges exist. Time is provided to brainstorm and share ideas for improvement, and workgroups are assigned for those tasks that cannot be accomplished during the scheduled meeting time. Also, time in the meeting is reserved for a provider from one of the specialties to educate the group on a topic particularly useful or pertinent in their respective area of expertise.

Recent presentation topics include education on endovascular procedures, hyperbaric oxygen therapy guidelines, and new updates on the treatment

“IT TAKES A WISE MAN TO LEARN FROM HIS MISTAKES, but an even wiser man to learn from others.”
– Zen Proverb

FIGURE 1. As the institution’s multidisciplinary limb salvage program has grown, so have the number of endovascular procedures performed annually at the institution.

FIGURE 2. Institutional decline in amputation rate, despite a significant increase in number of patients seen annually with peripheral artery disease (see Figure 1).
of osteomyelitis in patients with wounds and peripheral artery disease (PAD).

With these teamwork modalities in place, our institution is much better positioned to provide the best patient outcomes, patient experiences, and staff experiences. Figure 1 highlights the institution’s rapid growth in referrals of patients with PAD along with significant increase in annual endovascular revascularization procedures. Figure 2 demonstrates that with a significant influx of patients with PAD undergoing endovascular revascularization, the rate of amputation has dropped significantly.

The following 2 examples show how incorporating a multidisciplinary approach results in the positive outcomes.

**Case Study 1**

A 70-year-old male with uncontrolled type 1 diabetes mellitus (hemoglobin A1c 7.2) first presented to the endovascular practice 4 years ago. A diagnostic angiogram at that time showed mild disease with 10% to 30% stenosis of the posterior tibial (PT) artery bilaterally. This patient did not return for scheduled follow-up visits. One year ago his primary care physician (PCP) referred him to the wound clinic for a Grade 2 diabetic foot ulcer of the right plantar aspect (Figure 3), complicated by Charcot joint and prior fractures with hardware previously treated for infection. Initial x-ray and laboratory assessments were negative for osteomyelitis. He was examined by a wound podiatrist within a week and an endovascular specialist within 5 weeks. Diagnostic angiogram at this time showed 90% occlusion of the PT, much more severe than a repeat duplex ultrasound 2 weeks prior had indicated. An endovascular peripheral vascular intervention (PVI) was performed five weeks later for Rutherford grade V, after which he also started dual antiplatelet therapy. Two weeks post revascularization he began 49 treatments of hyperbaric oxygen therapy (HBO). Three weeks after starting HBO he was evaluated by an ID specialist who ordered 6 weeks of intravenous (IV) antibiotic therapy for possible infection at the location of his hardware. The following month, he underwent exostectomy of the fifth metatarsal base with the wound podiatrist to correct the structural pressure on the wound bed. After continued offloading, regular follow-up with the endovascular clinic, and biweekly wound visits, his ulcer healed within 12 weeks of his exostectomy. His original ulcer reopened the following month as result of wearing his old diabetic shoes and inserts but healed within 5 weeks, again with heavy offloading. He continues with monthly podiatry follow-ups and graduated to routine surveillance with the endovascular specialist. He remains healed 4 months later (Figure 4).

This case exemplifies the multifaceted approach necessary to heal a wound and preserve a limb in a patient at high risk for amputation. The patient saw many providers in four specialties (endovascular, wound, ID and endocrine). His treatment plan was aggressive and comprehensive, including PVI, HBO, exostectomy, IV antibiotics, and strict offloading by a knee walker.

**Case Study 2**

This second case study involves a 71-year-old female with history of uncontrolled type 2 diabetes mellitus (hemoglobin A1c of 8.6) with severe PAD and several prior PVIs in years past. She was referred to wound care by her PCP with a pulseless right foot, which included dry gangrene of the lateral foot and heel. During the wound visit, a nurse practitioner from endovascular came to the wound office to assess the patient, then worked with her collaborating physician to have the patient directly admitted. The next day the patient underwent PVI for a 100% occluded in-stent restenosis of the right mid superficial femoral artery (SFA) extending through the P3 segment of the popliteal artery. The proximal anterior tibial (AT) artery also presented with 100% occlusion in an underexpanded, previously placed stent. Treatment included an unsuccessful attempt at laser atherectomy followed by pretreatment with balloon angioplasty and final treatment with drug-coated balloons. The SFA chronic total occlusion went from 100% stenosis to <10% and AT revascularization resulted in 0% stenosis. Three weeks later, she received bilateral iliac stents and began collagenase ointment instead of betadine to the wounds. Despite refusing HBO therapy secondary to claustrophobia, this patient demonstrated complete healing within 2 months of presentation and 14 months later remains healed. She continues follow-up visits every 1 to 3 months with the endovascular clinic and her PCP.

This case underlines the importance of interdisciplinary communication and teamwork. A simple call from a wound nurse practitioner to an endovascular nurse practitioner resulted in the patient being admitted and revascularized within 24 hours, without involving the emergency department. Following revascularization, wound care staff provided debridement and advanced dressings, in addition to offloading and diet and diabetes recommendations. Again, the continuation of her excellent outcome was upheld through close follow-up.

**Conclusion**

These case studies highlight 2 successes of multidisciplinary collaboration. They demonstrate that providing timely, evidence-based, cooperative care gives the patient the best outcome. Many developments are in place to continue improving upon this collaborative relationship, including ongoing shadow experiences between the specialty groups, quarterly forums for discussion, and research collaboration. While this multidisciplinary relationship is relatively new and constantly evolving, a strong foundation is established. This foundation paves the way for further improvements, which will result in even better patient outcomes.
LIBERTY 360 Study of Peripheral Endovascular Device Interventions in 1,200 Patients With Symptomatic Lower Extremity Peripheral Artery Disease: Late-Breaking Results Presented at AMP 2016

George L. Adams, MHS, MD
From Rex Healthcare, Raleigh, North Carolina.

Many peripheral artery disease (PAD) clinical device trials are supported by commercial manufacturers and designed for regulatory device approval, with extensive inclusion/exclusion criteria to support homogeneous, nonconfounded patient populations. High-risk patients with advanced PAD, including critical limb ischemia (CLI), are often excluded to reduce the risk of adverse outcomes, leading to difficulty in translating trial results into real-world clinical practice. As a result, physicians have no direct guidance regarding the use of endovascular devices in these difficult but common scenarios. There is a need for objectively assessed studies to evaluate clinical, functional, and economic outcomes in a broader PAD patient population.

The LIBERTY 360 study aims to fill that void. This study is a prospective, observational, multicenter clinical study to evaluate acute and long-term clinical and economic outcomes of peripheral endovascular device intervention (PVI) in patients with distal outflow peripheral artery disease (PAD). Clinical Trials.gov (NCT01885412). This all-comers device study has liberal inclusion criteria and few exclusions. The LIBERTY 360 study enrolled 1,204 subjects in the following classifications: 502 patients in the ‘Claudicant Rutherford 2-3” arm; 602 in the ‘CLI Rutherford 4-5” arm; and 100 in the “CLI Rutherford 6” arm. The study will follow the subjects up to 5 years. In addition, the study utilizes 4 core laboratories for independent analysis. The LIBERTY 360 study will evaluate the following: procedural and lesion success, rates of major adverse events, duplex ultrasound interpretation of patency, wound status, quality of life, 6-minute walk test, and economic analysis. The LIBERTY patient score(s) will also be developed as a clinical predictor of outcomes to provide guidance for interventions in this patient population.

Procedural and 30-day results for all LIBERTY subjects were presented for the first time at the 2016 Amputation Prevention Symposium in Chicago. LIBERTY 360 investigated real-world PAD patients with rigorous study guidelines and independent oversight of outcomes. This study provides clinically relevant data to guide future PVI.

First Randomized Trial of the Stellarex Drug-Coated Balloon Demonstrates Superior Patency Rate and a Significantly Lower Rate of Reinterventions Over PTA

Henrik Schröder, MD
From the Center for Diagnostic Radiology and Minimally Invasive Therapy, Jewish Hospital, Berlin, Germany.

Twelve-month results from the ILLUMENATE European Randomized Clinical Trial (EU RCT) were recently presented for the first time at the Amputation Prevention Symposium in Chicago by Prof. Dr. Marianne Brodmann of Medical University in Graz, Austria. ILLUMENATE EU RCT was a prospective, randomized, multicenter, single-blinded trial. Patients were randomized (3:1 ratio) to treatment with the Stellarex Drug-coated Angioplasty Balloon or an uncoated angioplasty balloon. The Stellarex DCB is a low-dose (2 µg/mm² surface concentration of paclitaxel) next-generation DCB. The 12-month data showed a significantly higher primary patency rate of 89.0% in the cohort treated with Stellarex compared to 65.0% in the cohort treated with an uncoated angioplasty balloon (per Kaplan Meier estimates, P<.001 by log-rank test). Importantly, the higher patency rate led to a significantly lower rate of clinically driven target lesion revascularization in the Stellarex group (5.9% vs 16.7%, P=.04).

The enrolled population consists of patients with symptomatic occlusion and/or >70% stenosis in the superficial femoral and/or popliteal arteries. The trial design included rigorous controls to ensure data were unbiased and accurate. Oversight included an independent Clinical Events Committee and a data safety monitoring board; additionally, blinded angiographic and duplex ultrasound core laboratories (SyneCore and VasCore, respectively) analyzed procedural and diagnostic images. Hemodynamic, clinical, and functional outcomes will be evaluated annually for 3 years. Adverse events will be assessed through 5 years.

In total, 328 patients were enrolled at 18 centers in Austria and Germany; 294 patients were randomized to treatment with the Stellarex DCB (N=222) or an uncoated PTA balloon (N=72) following successful predilatation. The majority of patients suffered from severe claudication (82.8% in the Stellarex arm and 77.5% in the PTA arm). Risk factors were similar between the Stellarex and PTA groups including: hypertension (77.9% and 83.3%), hyperlipidemia (61.7% and 68.1%) and diabetes (37.4% and 36.1%). Baseline angiographic data per core lab assessment were also similar between groups. The mean lesion length was 7.2 cm and 7.1 cm and 19.2% and 19.0% of lesions were total occlusions in the Stellarex group and PTA group, respectively.

The 12-month primary patency rate observed in the Stellarex arm of this trial (89.0%) validates the early and promising patency rate demonstrated in the ILLUMENATE first-in-human study (89.5%) and is comparable with the highest published 12-month DCB patency rate (89.8%).1 The unique attribute of Stellarex is the ability to obtain these results with a low-dose drug coating. As a reference point, the comparable low-dose DCB has a reported 12-month patency rate of 73.5%.2

Final 12-month data from two additional trials, ILLUMENATE Global and ILLUMENATE Pivotal, the US IDE randomized trial, are expected to be released within the next 6 months.

REFERENCES
Written by a multidisciplinary panel of internationally recognized professionals, this book offers expert perspectives on techniques and technologies to overcome multilevel, multivessel complex peripheral vascular disease. Leading experts share tips and tricks to simplify the complexity of CLI revascularization and conquer vast unmet patient needs in CLI therapy. This textbook emphasizes outcomes research coupled with promising new device innovation to include low-profile devices and drug-eluting technologies that are changing the course of therapy for critical limb ischemia.

Jihad A. Mustapha, MD, FACC, FSCAI, is an internationally acclaimed interventional cardiologist who is well known for his groundbreaking work in critical limb ischemia (CLI). As a passionate advocate for CLI education, therapy and amputation prevention, he has been instrumental in advancing CLI therapy on a global level. In this book, he has successfully assembled an expert team of authors from the world’s leading centers to summarize the current best practices for the diagnosis and treatment of CLI.

For more information or to order, please visit www.CLIDiagnosticsandInterventions.com
Selected Abstracts From the 6th Annual Amputation Prevention Symposium

Endovascular Therapy of TASC-D Lesion in Critical Limb Ischemia
Ahmed Amro, MD; Alaas Gabi, MD; Mehran Ebrahimian, MD
From Marshall University-Joan C. Edwards School of Medicine, Huntington, West Virginia.

Introduction: CLI (Rutherford class 4-6) is a terminal stage of peripheral artery disease (PAD) and is defined by the presence of resting pain and/or tissue loss for at least 2 to 4 weeks that may require urgent revascularization to promote healing and prevent limb loss. For patients with inframural aortic and iliac obstructive atherosclerotic disease, the revascularization options are open surgery such as aortofemoral bypass and axillofemoral bypass or percutaneous intervention. Aortoiliac and aortofemoral bypass procedures are associated with 74% to 95% 5-year patency rates, respectively, which are comparable but not superior to percutaneous therapies. These operations may imply a significant morbidity and mortality on patients who are already at risk. Objectives: A 52-year-old smoker female patient presented with past medical history of hypertension, hyperlipidemia, and severe PAD with totally occluded infrarenal abdominal aorta just distal to the renal arteries and known right axillary femoral bypass with femorofemoral bypass. The patient had bilateral leg and foot pain at rest, diminished pulses, and ulceration of the legs. Ankle to toe brachial index (ABI and TBI) measurements were obtained and were abnormal (right ABI 0.27; TBI: 0.12. Left leg ABI 0.3; TBI 0.12). Computed tomography angiography showed total occlusion of the axillo-femoral bypass, totally infrafemoral aorta with reconstitution of peripheral circulation at the level of external iliac arteries bilaterally. These findings conformed by angiogram obtained by accessing the right radial artery. Methods: Using radial access in conjunction with ultrasound-guided access to the right and left femoral arteries respectively, percutaneous transluminal angioplasty and stents to the abdominal aorta using self-expandable stent, covered stents in the right and left common iliac arteries in a kissing fashion, as well as treatment of the right and left external iliac arteries was successfully achieved. Results: On 3-week follow-up, the patient’s symptoms of claudication resolved, and there were good pulses bilaterally, healing ulcers, and favorable ABI (Right leg ABI: 0.84; TBI: 0.68. Left leg ABI 0.82; TBI: 0.65). Conclusions: Endovascular treatment for infrarenal aortoiliac disease can be performed with lower morbidity than aortofemoral bypass and with better durability than axillofemoral bypass. Patients with TASC D lesions generally will be considered surgical candidates, but with advancement of technologies like drug-eluting balloons, drug-eluting stents, and others, endovascular therapy might be an option on a case-by-case basis.

Clinical Topography Correlates With Angiographic Severity Grade in Diabetic Wagner 2-4 Neuroischemic Foot Ulcers
François Triffaux, MD; Romain Lacrosse, LPHN; Vlad A. Alexandrescu, MD
From Princess Paola Hospital, Luxembourg, Belgium.

Introduction: Wound-targeted revascularization following the foot angiographies was evoked to provide encouraging clinical results, particularly in diabetic, collateral depleted, neuroischemic foot ulcers. Objectives: The present study was conceived to assess eventual angiographic-related significance between clinical features and individual angiographic findings in diabetic patients with critical limb ischemia (CLI) foot ulcers. Methods: A homogeneous series of 133 Rutherford category 5 ischemic limbs having Wagner grade 2-4 diabetic neuroischemic wound were analyzed in a prospective institutional database. Limbs with 3 or more ulcers, or showing Rutherford 6, and/or Wagner 5 ischemic irrecoverable wounds were excluded from analysis. Angiographic atherosclerotic characteristics were stratified upon specific tibial and foot arteries severity score (n=0-16). The extent of severe stenoses (>70%), the presence of chronic total occlusions, arterial calcifications, and the integrity of foot arches were detailed in specific tibial (n=0-6) and foot arteries (n=0-10) grading scales. The topography of foot ischemic ulcers was compared before and after debridement to the severity and location of related below-the-knee atherosclerotic disease. Results: Among all presentations, 90 cases (68%) presented 2, and 43 limbs (32%) 2 concomitant wounds, which were further studied in 2 parallel groups. In 105 cases (79%) de novo ulcers were noted, and in 28 limbs (21%) relapsing ulcers were noted. After cumulative angiographic score analysis, in the “single wound” group 61/90 wounds (68%) accurately associated specific foot angiome to corresponding tibial and/or foot nourishing arteries at highest atherosclerotic severity scores (12/16-16/16). In the same group, 23/90 limbs (25%), including most of the forefoot lesions, fitted clinical with angiographic findings concerning two angiomes affection, while in 6 cases (7%) no relation was found between the severity of arterial disease and the foot ulcer’s location. Among the “two wounds” group, matched clinical and angiographic correlation for one angiome was found in 10 (23%) cases, for 2 or 3 angiomes in 27 (63%) presentations, while in 6 cases (14%) no correspondence was noted. Global analysis showed significant clinical and angiographic atherosclerotic matching for the “Single wound” (P<0.001, RR=7.72, CI=3.508-17.02), also for the “two wounds” groups (P<0.001, RR=3.777, CI=1.721-8.290), before and/or after debridement. Conclusions: Our registry data suggest acceptable clinical and angiographic correlation concerning foot angiomes affection in early CLI stages. It appears that the lesser the extent of inflammation and necrosis (duration of ischemia and concurrent factors), the clearer the clinical and iconographic angiome orientation in diagnostic.

An Impossible Meeting: Combined Radio-Pedal Access for Peripheral Intervention
Alaas Gabi, MD; Ahmed Amro, MD; Mehran Ebrahimian, MD
From Marshall University-Joan C. Edwards School of Medicine, Huntington, West Virginia.

Introduction: Antegrade radial and retrograde transpedal endovascular intervention is being used as an alternative approach for peripheral angioplasty. We present a case using combined radial and pedal access for angioplasty in a patient with severe bilateral peripheral vascular disease and occluded peripheral bypass graft. Objectives: A 55-year-old female with history of extensive peripheral vascular disease status post right femorofemoral and left femoropopliteal bypass sugery, presented with claudication. Functional study showed evidence of multilevel severe arterial disease. Angiogram and bilateral lower extremity peripheral angiograms were performed via pedal access. The right common iliac artery was patent, there was a stent across the right external iliac with total occlusion in the distal segment, and the femoral artery was occluded as well as the proximal portion of the SFA with reconstitution at the level of the mid superficial femoral artery (SFA). The popliteal artery was patent with good distal run-off. The left common, external, and internal iliac arteries were patent. The left common femoral artery had high-grade stenosis in its proximal segment, the profunda femoris was patent, and the SFA was totally occluded proximally with reconstitution distally at the proximal popliteal artery with good distal 3-veesl run-off. Femoropopliteal and femorofemoral grafts were occluded. Right-side angioplasty was planned as well as a staged angioplasty on the left side in a separate procedure. Methods: Right pedal access was obtained with ultrasound guidance. A balloon was inserted and inflated in the common femoral and proximal SFA at different levels. Angiography showed high-grade ostial disease in the profunda femoris. A wire was advanced through the left radial access into the profunda. A balloon was inserted to the proximal profunda and another balloon was inserted through the pedal access to the common femoral. Both balloons were inflated at the same time in the same fashion. Then, through the radial access another balloon was inserted and inflated in the right external iliac artery. Angiograms obtained afterward showed dissection in the proximal edge of the external iliac artery stent that was placed previously. A stent was then inserted and deployed in the right external iliac artery overlapping the previous stent. Angiogram imaging then showed a good outcome. Results: Angiograms obtained postprocedure showed a good outcome. Using
pedal and radial access in peripheral angioplasty could represent a good alternative to traditional femoral access. On the one hand, it is associated with a quicker recovery and avoidance of transfemoral access complications such as femoral pseudoaneurysm and retroperitoneal bleeding. On the other hand, the small diameter of the dorsalis pedis and radial artery enhances the control and pushability of devices during angioplasty. Studies have shown that crossing totally occluded peripheral vessels from the lower cap is usually more successful. Of importance also is that through retrograde approach there is less chance of entering unwanted branches given the caudal fashion of collateral branching in peripheral vessels. Conclusions: Radial and pedal access could represent a good alternative approach to the traditional femoral approach.

Long-Term Outcomes of Endovascular Treatment of Critical Limb Ischemia in Very Elderly Chinese Patients: A Single Hong Kong Center Experience

Bryan Yan, MD; Gormin Tam, MD; Christy Chan†; Lily Li†; Olivia To, RN†; James Lau, MD† From 1The Chinese University of Hong Kong Prince of Wales Hospital, Hong Kong, and 2The Chinese University of Hong Kong, Hong Kong.

Introduction: Primary amputation had been the predominant treatment for critical limb ischemia (CLI) in Hong Kong until the recent introduction of endovascular therapy (EVT). There is a paucity of data involving Chinese elderly patients with CLI.

Objectives: We aim to determine long-term outcomes of EVT for CLI in elderly patients aged 75 years and older. Methods: Retrospective analysis of consecutive patients >75 years who underwent attempted EVT for CLI between January 2009 and December 2015 at a single tertiary referral hospital in Hong Kong. Minimum follow-up was 6 months with a maximum of 109 months. Primary endpoint was amputation-free survival (AFS) at 12 months. Secondary endpoints included 12-month freedom from any major amputation (MUA) and major vascular reintervention in the index limb.

Results: Endovascular therapy was attempted in 151 critically ischemic limbs of 128 patients (35.9% men, mean age 82.8 ± 4.8 years). Of these, 122 patients (95.3%) had significant comorbidities such as coronary artery disease (24.2%), stroke (23.4%), chronic renal failure/dialysis (10.2%), diabetes (57.0%) and hypertension (91.4%). Indication for revascularization was Rutherford class 4 (n=31, 20.5%), 5 (n=106, 70.2%) and 6 (n=14, 9.3%). The anatomical segments involved were iliac (16.2%), superficial femoral (68.9%), popliteal (27.0%) and infrapopliteal (57.4%). Technical success rate was 93.2%. Early complications occurred in 12.6% of procedures. The 30-day mortality rate was 7.8% (n=10). Median (range) in-hospital stay was 7 (1 to 84) days. There were 20 major limb amputations (13.2%) during the study period. Six-, 12-, 24-, and 36-month AFS rates were 78.9%, 73.4%, 61.7%, and 56.3% and MALE-free survival rates were 86.1%, 83.4%, 80.8%, and 80.8%, respectively. Conclusions: Endovascular therapy is safe and effective in preventing major amputations in very elderly patients with CLI. However, mortality rates remained high, which may reflect underlying comorbidities of this group of patients.

Ex-Vivo CTO Crossing With a Novel Shock Wave-Energized Guidewire

Louis-Philippe Riel†; Manuel Charlebois-Ménard†; Simon Bérubé, MD; Marc-Antoine Despatys, MD‡; Marianne Brodmann, MD; Andrew Benko, MD; Éric Thérasse, MD; Steven Dion†; Martin Brouillette, PhD From 1SoundBite Medical Solutions Inc., Montreal, Canada; 2Sherbrooke University Hospital, Quebec, Canada; 3Medical University Graz, Graz, Austria, and 4Montreal University Hospital, Montreal, Canada.

Introduction: Shock waves, or short-duration high-amplitude pressure pulses, have successfully been used in various medical therapies. We use a novel generator to generate shock waves that are focused into the proximal end of a guidewire, referred to as the ShockWire. The shock waves then propagate to the distal tip of the ShockWire, which facilitate device placement into calcified and/or fibrotic chronic total occlusions (CTO).

Objectives: In the present study, we examine the capability of this system to cross ex-vivo CTO artery segments obtained from leg amputation in a clinically representative setting.

Methods: Below-the-knee artery trees containing CTOs are dissected from leg amputations and are incorporated into a full vascular model. CTO crossings are performed with the ShockWire device under fluoroscopy in an angiography laboratory. In particular, the procedure used a 0.018˝ guidewire platform along with a Rubicon 18 support catheter. CTO crossing is first attempted with a commercially available guidewire, then with the unpowered ShockWire and finally with the powered ShockWire.

Results: The powered device was found to be able to cross stenoses and CTOs located in the popliteal, anterior tibial, and posterior tibial arteries that could not be crossed with conventional guidewires or the unpowered device. The powered device was found to be reusable by applying a slight bend near the distal tip region which allowed the device to remain intraluminal during and after crossing and also minimized risks of perforation. In some cases, it was possible to advance the support catheter over the device after a successful crossing.

Conclusions: This novel device was found to be compatible with current guidewire-based workflow and demonstrated the ability to cross peripheral CTOs on the bench in a clinically representative setting.

Rhabdomyolysis Complicating Carbon Dioxide Angiography: A Case Report

Sinan Sarsam, MD, Patrick Alexander, MD From Providence Heart Institute, Southfield, Michigan.

Introduction: Carbon dioxide digital subtraction angiography (DSA) has been used as an alternative to iodinated contrast, both for diagnostic and therapeutic purposes in patients with advanced kidney disease and serious allergic reactions. Its safety was established in prior studies for use in the peripheral arterial system.

Methods: A 67-year-old male with hypertension, diabetes, stage IV chronic kidney disease, coronary and peripheral vascular disease, and bilateral lower extremity ulcerations (Rutherford 3), underwent a CO2-guided DSA of the lower extremities showing severe bilateral posterior tibial artery disease. He gradually developed significant weakness with inability to stand on his legs, and presented to the emergency department 2 days after the procedure. On examination, vital signs were stable, and he was able to lift his legs while in bed. There were chronic skin changes, with evidence of diabetic neuropathy. Laboratory workup showed elevation of blood urea nitrogen and creatinine to 79 mg/dL and 5.1 mg/dL, respectively (baseline creatinine 2.8 mg/dL). Total creatine phosphokinase was 4,839 u/L. Magnetic resonance imaging of the spine ruled out spinal artery embolism. He was treated with IV fluids and his condition gradually improved. His creatinine was 2.5 mg/dL on discharge. He was seen 7 weeks later and was doing well with stable kidney function.

Results: Carbon dioxide angiography is useful in patients with advanced kidney disease to decrease the risk of contrast-induced nephropathy. However, it is not without its own risks. Carbon dioxide should not be injected in the thoracic aorta because of risks of neurotoxicity and cardiac arrhythmias. Carbon dioxide can get trapped within the vascular space, the so-called “vapor lock,” especially in patients with poor cardia output (this patient had normal EF). Delayed clearing of CO2 can exhibit the vasoconstriction in CO2, and increase the risk of the symptoms of dizziness, lipoed reticulitis, and rhabdomyolysis. Possible air contamination may also play a role. These complications may be reduced with use of a small volume of CO2 per imaging run (<50 cc) and allowing adequate timing between injections to help clear the CO2 (both were followed in this case). Changing the patient’s position may also help to clear CO2.

Conclusions: Carbon dioxide digital subtraction angiography is a good alternative to iodinated contrast in patients with renal failure. Given the increasing use of this technique in patients with advanced peripheral vascular disease, awareness of potential adverse events is crucial.

The Maine Amputation Prevention Initiative


Introduction: Amputation is extremely prevalent in rural and poor areas in every state in the United States. Patients with Peripheral arterial disease (PAD) experience high rates of lower-extremity amputation (LEA) due to complications related to access to care, lack of comprehensive wound care programs and lack of vascular surgeons capable of performing minimally invasive lower-extremity stenting in efforts to reduce LEA in Maine. We will be compiling statewide data from the Maine Health Data Organization (MHDO) in efforts to determine the number of lower-extremity amputations, level of lower-extremity amputations and pre- and postamputation treatments in this retrospective study. We will examine trends in LEAs in Maine and associate incidences with cost per amputation.

Objectives: We will establish that the introduction of PAD studies and earlier intervention on suspected PAD patients will reduce the LEA rate substantially in Maine. We will measure LEAs in a retrospective analysis of data held by the MHDO from the Maine Health Data Organization (MHDO) in efforts to determine the number of lower-extremity amputations, level of lower-extremity amputations and pre- and postamputation treatments in this retrospective study. We will examine trends in LEAs in Maine and associate incidences with cost per amputation.

Methods: Retrospective analysis of patients admitted to hospitals in Maine from 2013 to 2015 who experienced an LEA at any level. The study includes a demographic study, evaluation of preamputation and postamputation treatment, incidence of PAD studies and earlier intervention on suspected PAD patients will reduce the LEA rate substantially in Maine. We will measure LEAs in a retrospective analysis of data held by the MHDO from the Maine Health Data Organization (MHDO) in efforts to determine the number of lower-extremity amputations, level of lower-extremity amputations and pre- and postamputation treatments in this retrospective study. We will examine trends in LEAs in Maine and associate incidences with cost per amputation.

Results: We will establish that the introduction of PAD studies and earlier intervention on suspected PAD patients will reduce the LEA rate substantially in Maine. We will measure LEAs in a retrospective analysis of data held by the MHDO from the Maine Health Data Organization (MHDO) in efforts to determine the number of lower-extremity amputations, level of lower-extremity amputations and pre- and postamputation treatments in this retrospective study. We will examine trends in LEAs in Maine and associate incidences with cost per amputation.

Discussion: We will discuss the results of this study and how they impact on the future of ischemic limb salvage efforts in Maine.

Conclusions: We will establish that the introduction of PAD studies and earlier intervention on suspected PAD patients will reduce the LEA rate substantially in Maine. We will measure LEAs in a retrospective analysis of data held by the MHDO from the Maine Health Data Organization (MHDO) in efforts to determine the number of lower-extremity amputations, level of lower-extremity amputations and pre- and postamputation treatments in this retrospective study. We will examine trends in LEAs in Maine and associate incidences with cost per amputation.
Lower-Extremity Amputations Within a Veteran Population
Sarah Park, DPM; Anna Tien, DPM; Jake Ruff, DPM; Patrick Sanchez, DPM; Matthew Garoufalis, DPM
From Jesse Brown VA Medical Center, Chicago, Illinois.

Introduction: The CDC estimated that 29.1 million adults in the United States had diabetes in 2014. An estimated 5% to 7% of this population develops diabetic foot ulcerations, and up to 8% of diabetes-related lower extremity amputations are preceded by foot ulcers. Amputation is 10 times as likely in patients with diabetes. The morbidity and mortality following a lower extremity amputation are profound. Patients have shown 5-year mortalities ranging from 64.8% for toe amputations to 85.7% following above-knee amputations.

Objectives: The purpose of this study was to evaluate the current trends of distal vs proximal amputations and the significance of comorbidities on the amputations. Methods: IRB approval was obtained from the University of Illinois at Chicago. This is a retrospective review of 67,415 patients who underwent lower-extremity amputations between fiscal years 2000 and 2015 through the Veterans Health Administration data. The population included amputation diagnoses and procedure codes recorded within the VHA data. This included distal to proximal lower-extremity amputations. The population consisted of patients with diabetes, patients without diabetes, and combat veterans. The study included a total of 67,415 patients, representing 129,482 amputations. The patients had a range of comorbidities, defined as normal risk (diabetes, smoking history), low or moderate risk (foot deformity, peripheral neuropathy, PVD), or high risk (previous amputation, Charcot, end-stage renal disease, gangrene, nonhealing ulcer, osteomyelitis, previous PVD surgery).

Results: The results demonstrate a clear increase in the number of digital amputations over the past 15 years. On the contrary, proximal lower-extremity amputations have remained somewhat stable despite an increasing diabetic population. Partial foot amputations and ankle disarticulations remained at a stable low number throughout the study. A test showed that there is a statistical difference between the average number of procedures per year, and all amputations per year, and the associated mortality. Between the number of digital vs proximal amputations.

Conclusions: Three-dimensional data demonstrated that there is a trend toward fewer digital amputations and more proximal amputations. Amputation rates are changing over time and to compare the overall function and limb-salvage perspective due to the high mortality rates ranging from 41.4% for toe amputations to 85.7% following above-knee amputations.

Final Results of the PRISM Trial for Revascularization of Peripheral and Visceral Arterial Occlusions
George Adams, MD1; James Benenati, MD2; Richard Saxon, MD1; Luke Sewell, MD3; Corey Teigen, MD4
From 1North Carolina Heart and Vascular Research, Raleigh, North Carolina, 2Miami Cardiac and Vascular Institute, Miami, Florida, 3San Diego Cardiovascular and Vascular Institute, San Diego, California, 4Adventist Midwest, Hinsdale, Illinois, and 5Sanford Health, Fargo, North Dakota.

Introduction: The PRISM trial was a single-arm, multicenter case review trial enrollment in 4 centers consisting of peripheral or visceral occlusions receiving thrombectomy therapy. Patients suffering from peripheral occlusive diseases face the risk of long-term damage, amputation, and even death. With a proven track record for success in the neurovascular system, the Penumbra System was thus adapted into the Indigo System, targeting recanalization of occlusions in the periphery. Objectives: The PRISM study aimed to determine the safety and technical effectiveness of the Penumbra/Indigo System in treatment of peripheral and visceral arterial occlusions. Methods: The PRISM trial concluded with 85 enrolled patients. Patient admission required satisfying the criteria of confirmed occlusion of the periphery (TIMI 0-1); enrolled patients included those suffering from acute limb ischemia, failed thrombolysis, and embolus of proceeding intervention. The primary outcome of the study assessed the rate of successful recanalization, defined as TIMI 2-3, and procedure-related serious adverse events within 24 hours of the index procedure. Results: Enrolled patients yielded a median age of 69 (interquartile range, 60-78) years. Occlusion sites varied; however they can be generalized to popliteal/tibial (54.1%), femoral/superficial femoral artery (34.1%), and other (11.9%). Patients in whom Penumbra/Indigo aspiration thrombectomy was attempted as frontline (50.6%, 43/85) yielded successful thrombectomy to TIMI 2-3 in 81.4% (35/43) of cases; 6 additional patients (9.3%, 41/43) achieved TIMI 2-3 recanalization following adjunctive therapies. In 14 patients (16.5%) who received lytic therapy prior to aspiration thrombectomy, 92.9% (13/14) achieved successful recanalization from Penumbra/Indigo use alone; no change was observed after adjunctive therapies. A similar rate of success (91.1%) for thrombectomy alone was achieved in patients with prior mechanical thrombectomy (17.6%, 15/85); post interventions, 100% within this cohort achieved TIMI 2-3. Lastly, cohorts with combined lytic and mechanical therapies prior (15.3%, 13/85) reported 100% success immediately post aspiration thrombectomy alone. Overall, aspiration thrombectomy alone was successful in restoring vessel patency to TIMI 2-3 in 88.1% (74/84) of patients at a median procedural time of 67.5 minutes (interquartile range, 54-81) from puncture; this outcome further improved to 96.8% secondary to all interventions. The safety outcome at 24 hours included 17 serious adverse events in 10 patients; none were considered device related. Conclusions: Final results from the PRISM trial appear promising, exhibiting high rates of recanalization and low risk. These positive results support the broad application of the Penumbra/Indigo System both as a frontline and salvage therapy. Future controlled studies are encouraged to further validate the current findings.

Occlusion Perfusion Catheter (OPC) Next Generation Treatment for Restenosis
Rex Teetsink, MD
From Wound Care 360, Olathe, Kansas.

Introduction: Advanced Catheter Therapies (ACT) has designed the Occlusion Perfusion Catheter (OPC) to function as a universal agent delivery system that will accommodate any therapeutic agent, including pharmaceuticals, biologics, and live cells. The OPC is a 5-lumen catheter designed with proximal and distal occlusion balloons, a center space occupying balloon, an inflow port, an outflow port, and a guidewire lumen compatible with 0.014” guidewires, sheath-compatible, higher pressure. A fiber-optic pressure sensor is incorporated into the inflow lumen to monitor treatment pressure and balloon occlusions define the treatment region. Objectives: To demonstrate the advantages of the OPC universal drug-delivery system compared to drug-coated balloons. Methods: The proximal and distal occlusion balloons are inflated simultaneously to control blood flow and create a treatment chamber. In addition, they serve to prevent systemic distribution of the agent. The fourth and fifth lumens are for inflow and outflow ports located within the established treatment chamber. The trapped blood is removed from the treatment chamber by flushing with saline. The space-occupying balloon can be inflated to minimize the amount of therapeutic agent required, when indicated. This balloon never touches the vessel wall. Once the blood has been evacuated, the therapeutic agent is delivered. A sensor monitors, controls, and optimizes pressure within the chamber for penetration into the media of the vessel wall, longitudinally and circumferentially. Results: Preclinical results showed that confocal analysis of the vessel wall demonstrated delivery of fluorescent paclitaxel within media and adventitial layer, circumferentially and longitudinally. PK analysis demonstrated a straight line of 0.1 mcg/ml for 72 hours. According to Axel et al (Circulation 1997;96:636-645), the effective range of paclitaxel (0.025 – 0.15mcg/ml) is a 10,000-fold lower range than needed to achieve 99% inhibition of human arterial smooth muscle cells, maintaining normal intimal endothelial function by non-coating. It eliminates the need for vessel/balloon sizing, delivers multiple agents, supports multiple use in the same patient, above and below the knee, delivers live cells with minimal mechanical damage at a wide range of pressures. Conclusions: The OPC delivers an agent circumferentially and longitudinally into the vessel wall. It delivers the effective range of paclitaxel for 90% to 99% inhibition of human arterial smooth muscle cells, maintaining normal intimal endothelial function by non-coating. It eliminates the need for vessel/balloon sizing, delivers multiple agents, supports multiple use in the same patient, above and below the knee, delivers live cells with minimal mechanical damage to the cell membrane, negates blood/agent admixture, minimizes systemic effect via flushing, and decreases cost.

A New Closure Device: How to Close Large-Bore Sheaths With a Single Device, Leaving Nothing Behind
Rex Teetsink, MD
From Wound Care 360, Olathe, Kansas.

Introduction: Virtual Care 360 has designed a closure device, SiteSeal, which simulates external compression, but removes the associated variables. It applies inertant pressure to the vessel wall access site by utilizing internal stainless steel coils, which function as shock absorbers to dampen blood vessel pressure fluctuations. Objectives: To demonstrate the advantages of the Site Seal Closure Device compared to other closure devices. Methods: SiteSeal utilizes a number 2 Vicryl suture to make a “Z” stich, which holds the SiteSeal device in place, and closes the arteriotomy site in a linear fashion. The Z stich is placed by entering the soft tissue at the skin insertion site of the sheath. If the clinician is right handed, the first entrance is 1 cm east of the sheath, passing under the sheath and exits 1 cm west of the sheath. The second entrance is 1 cm above the skin insertion of the sheath and 1 cm to the east. The needle then crosses up and over the sheath and back down into the soft tissue and exits 1 cm west of the sheath. The 2 ends of the Z stich form a double half knot, which when closed, creates an “X” over the arteriotomy site. Bioseal powder is placed around the sheath and half knot. The device is cocked by turning the cross bar horizontally and applying pressure, which loads the springs. It is then centered over the sheath at the arteriotomy site with the incline plane facing north. The dilator is removed from the sheath. The two suture ends are pulled tight against the sheath at pressure is applied to the device, closing the Z stich into an “X” over the arteriotomy site, and the sheath is removed. The suture ends are pulled up through the designed slots and tied into the notched slot of the cross bar. The loaded springs are released by turning the cross bar back to a vertical position. Once the device is activated, the pressure created by the Z stich continues to elevate the artery and folds in the soft tissues surrounding the arteriotomy site, closing the site in a linear fashion. The roof is placed and Iegaderm is applied for stabilization. Results: There have been 38 EVAR and 18 Impella procedures performed using SiteSeal without any hematoma formation at discharge and at 24-hour, 7-day, and 30-day follow-up. Conclusions: SiteSeal does have the ability to close large bore sheaths with a single device, leaving nothing behind. Associated advantages are that there is no limitation from sheath size, including EVAR, TEVAR, TAVR. There is no patient limitation in terms of size, anticoagulation, or calcification. Deployment is simple and rapid, the device allows immediate reaccess, it minimizes patient discomfort, allowing immediate head elevation to 30° with no restriction to leg movement. The device also enables early ambulation, with nothing left behind, and the potential of minimal risk of vessel wall injury, infection, or embolization.
EACH YEAR OVER 75,000 AMPUTATIONS OCCUR GLOBALLY DUE TO CLI

Despite advances in revascularization options, physicians and patients remain unaware of the alternatives to amputation.

Join this vascular specialist advocacy group to raise awareness of this limb threatening disease.

WWW.CLIGLOBALSOCIETY.ORG
The LUTONIX® Global SFA Real-World Registry demonstrated safety and effectiveness in 691 patients—confirming the positive results reported in LEVANT 2. The LUTONIX® 035, the #1 selling DCB, has the largest DCB product offering on the U.S. Market.1

LUTONIX® 035 | 5F
Drug Coated Balloon PTA Catheter

1 Primary efficacy endpoint is defined as freedom from TLR at 12 months. Total of 639 subjects were evaluable for the primary efficacy endpoint analysis. The 12 month TLR-Free rate by subject counts at 12 months was 93.6%. The Kaplan-Meier estimates TLR-Free survival was 94.2% at 12 months and 89.2% at 24 months. TLR-Free survival by lesion location was 94.8% (n=483) for SFA, 94.0% (n=86) for popliteal, and 92.2% (n=121) for patients with lesion in both SFA and popliteal.

2 Calculated based on dollar sales. MRG Moving Annual Total 2016 Data published May 2016 based on hospital sample. Includes third party vendor sales for Lutonix®. ©2016 Millennium Research Group, Inc. All rights reserved. Reproduction, distribution, transmission or publication is prohibited. Reprinted with permission.